hydroxychloroquine has been researched along with Coronary Artery Disease in 5 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to determine whether hydroxychloroquine (HCQ) usage is associated with incidental risk of coronary artery diseases (CAD) in patients with rheumatoid arthritis (RA)." | 7.88 | Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study. ( Chiou, JY; Hung, YM; Lin, L; Wang, PYP; Wang, YH; Wei, JC, 2018) |
| " Hydroxychloroquine, an original antimalarial drug, prevents inflammation caused by lupus erythematosus and rheumatoid arthritis." | 7.83 | Hydroxychloroquine, a promising choice for coronary artery disease? ( Bai, X; Li, R; Liu, J; Liu, M; Ma, Q; Sun, L; Wei, Y; Wu, Y; Yang, Y; Yuan, Z; Zhang, L; Zhao, Q; Zhou, J, 2016) |
| "The aim of this study was to determine whether hydroxychloroquine (HCQ) usage is associated with incidental risk of coronary artery diseases (CAD) in patients with rheumatoid arthritis (RA)." | 3.88 | Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study. ( Chiou, JY; Hung, YM; Lin, L; Wang, PYP; Wang, YH; Wei, JC, 2018) |
| " Using propensity score matching, two of four network-based predictions are validated in patient-level data: carbamazepine is associated with an increased risk of coronary artery disease (CAD) [hazard ratio (HR) 1." | 3.88 | Network-based approach to prediction and population-based validation of in silico drug repurposing. ( Barabási, AL; Cheng, F; Desai, RJ; Handy, DE; Loscalzo, J; Schneeweiss, S; Wang, R, 2018) |
| " Hydroxychloroquine, an original antimalarial drug, prevents inflammation caused by lupus erythematosus and rheumatoid arthritis." | 3.83 | Hydroxychloroquine, a promising choice for coronary artery disease? ( Bai, X; Li, R; Liu, J; Liu, M; Ma, Q; Sun, L; Wei, Y; Wu, Y; Yang, Y; Yuan, Z; Zhang, L; Zhao, Q; Zhou, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Everaert, BR | 1 |
| Muylle, J | 1 |
| Bartholomeus Twickler, T | 1 |
| Lee, KH | 1 |
| Kim, JS | 1 |
| Hong, SH | 1 |
| Seong, D | 1 |
| Choi, YR | 1 |
| Ahn, YT | 1 |
| Kim, KS | 1 |
| Kim, SE | 1 |
| Lee, S | 1 |
| Sim, W | 1 |
| Kim, D | 1 |
| Jun, B | 1 |
| Yang, JW | 1 |
| Yon, DK | 1 |
| Lee, SW | 1 |
| Kim, MS | 1 |
| Dragioti, E | 1 |
| Li, H | 1 |
| Jacob, L | 1 |
| Koyanagi, A | 1 |
| Abou Ghayda, R | 1 |
| Shin, JI | 1 |
| Smith, L | 1 |
| Hung, YM | 1 |
| Wang, YH | 1 |
| Lin, L | 1 |
| Wang, PYP | 1 |
| Chiou, JY | 1 |
| Wei, JC | 1 |
| Cheng, F | 1 |
| Desai, RJ | 1 |
| Handy, DE | 1 |
| Wang, R | 1 |
| Schneeweiss, S | 1 |
| Barabási, AL | 1 |
| Loscalzo, J | 1 |
| Sun, L | 1 |
| Liu, M | 1 |
| Li, R | 1 |
| Zhao, Q | 1 |
| Liu, J | 1 |
| Yang, Y | 1 |
| Zhang, L | 1 |
| Bai, X | 1 |
| Wei, Y | 1 |
| Ma, Q | 1 |
| Zhou, J | 1 |
| Yuan, Z | 1 |
| Wu, Y | 1 |
1 review available for hydroxychloroquine and Coronary Artery Disease
| Article | Year |
|---|---|
Risk factors of COVID-19 mortality: a systematic review of current literature and lessons from recent retracted articles.
Topics: Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Asian Peopl | 2020 |
4 other studies available for hydroxychloroquine and Coronary Artery Disease
| Article | Year |
|---|---|
Emerging cardiological issues during the COVID-19 pandemic.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Coronary Artery Disease; Coronavirus Infect | 2020 |
Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Comorbidity; Coronary Artery Disease; Data | 2018 |
Network-based approach to prediction and population-based validation of in silico drug repurposing.
Topics: Carbamazepine; Computer Simulation; Coronary Artery Disease; Databases, Factual; Drug Repositioning; | 2018 |
Hydroxychloroquine, a promising choice for coronary artery disease?
Topics: Animals; Antimalarials; Arthritis, Rheumatoid; Coronary Artery Disease; Disease Models, Animal; Huma | 2016 |